translation agency

NLM AIDSLINE
Progression and survival in IVDU's: different from hetero- or homosexually infected people with HIV? The Swiss HIV Cohort Study SHCS).
von Overbeck J; Egger M; Schoep M; Ledergerber L; Smith GD; Furrer H;
November 30, 1993
Int Conf AIDS. 1993 Jun 6-11;9(1):287 (abstract no. PO-B01-0910). Unique

OBJECTIVE: To study progression and survival in patients infected by IVDU, as compared to hetero- or homosexually infected patients in the SHCS. METHODS: Study endpoints were decrease of CD4 cells to < 200, and death. Kaplan-Meier functions and Cox regression analyses were computed for patients with > or = 1 follow-up visit. Sample sizes were 1897 IVDUs, 1400 Homo- (HS) and 739 Heterosexuals (HET) for endpoint death, and 1350 IVDUs, 885 HS and 527 HET for CD4 < 200. Patients were included in the SHCS at any stage. RESULTS: IVDU's were younger than HET and HS (29; 33; 37 years resp.) and had higher median CD4 counts at entry (370; 350; 300). 35% were female (HET: 53%). Estimates for median survival time since inclusion were 5.2 years in IVDU's, 4.6 in HET and 4.2 in HS (p < 0.001). Hazard ratios (95% confidence intervals) were: TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: Disease progression and survival appear to be similar in IVDU's, HS and HET when baseline differences are taken into account. This may be explained by equal access to medical care, treatment and counselling among patients enrolled in the SHCS.

*HIV Infections/COMPLICATIONS *Substance Abuse, Intravenous/COMPLICATIONS

www.aegis.org